Robert K. Zeldin

3.3k total citations · 1 hit paper
61 papers, 2.4k citations indexed

About

Robert K. Zeldin is a scholar working on Physiology, Immunology and Allergy and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Robert K. Zeldin has authored 61 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Physiology, 31 papers in Immunology and Allergy and 18 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Robert K. Zeldin's work include Asthma and respiratory diseases (32 papers), Allergic Rhinitis and Sensitization (31 papers) and Respiratory and Cough-Related Research (8 papers). Robert K. Zeldin is often cited by papers focused on Asthma and respiratory diseases (32 papers), Allergic Rhinitis and Sensitization (31 papers) and Respiratory and Cough-Related Research (8 papers). Robert K. Zeldin collaborates with scholars based in United States, France and Germany. Robert K. Zeldin's co-authors include Gregory P. Geba, Spero R. Cataland, Filip Callewaert, Paul Knöbl, Marie Scully, Flora Peyvandi, Johanna A. Kremer Hovinga, Hilde De Winter, Farid Kianifard and Marc Massanari and has published in prestigious journals such as New England Journal of Medicine, Blood and CHEST Journal.

In The Last Decade

Robert K. Zeldin

60 papers receiving 2.3k citations

Hit Papers

Caplacizumab Treatment for Acquired Thrombotic Thrombocyt... 2019 2026 2021 2023 2019 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
    2019 602 citations Marie Scully, Spero R. Cataland et al. profile →

Peers

Robert K. Zeldin
Steven E. Carsons United States
Mary Ann Mascelli United States
Céline C. Berthier United States
Gian Carlo Avanzi Italy
Eric R. Hurd United States
Katayoon Goodarzi United States
B. Sassolas France
Hirokazu Imai Japan
Gloria R. Gallo United States
Yogendra Kanthi United States
Steven E. Carsons United States
Robert K. Zeldin
Citations per year, relative to Robert K. Zeldin Robert K. Zeldin (= 1×) peers Steven E. Carsons

Countries citing papers authored by Robert K. Zeldin

Since Specialization
Citations

This map shows the geographic impact of Robert K. Zeldin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert K. Zeldin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert K. Zeldin more than expected).

Fields of papers citing papers by Robert K. Zeldin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert K. Zeldin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert K. Zeldin. The network helps show where Robert K. Zeldin may publish in the future.

Co-authorship network of co-authors of Robert K. Zeldin

This figure shows the co-authorship network connecting the top 25 collaborators of Robert K. Zeldin. A scholar is included among the top collaborators of Robert K. Zeldin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert K. Zeldin. Robert K. Zeldin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Scully, Marie, Spero R. Cataland, Flora Peyvandi, et al.. (2017). Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. Blood. 130(Suppl_1). LBA–1. 16 indexed citations
2.
Roux, Michel J., et al.. (2016). Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber. Journal of Allergy and Clinical Immunology. 138(2). 451–458.e5. 48 indexed citations
3.
Bergmann, Karl‐Christian, Pascal Demoly, Margitta Worm, et al.. (2014). Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. Journal of Allergy and Clinical Immunology. 133(6). 1608–1614.e6. 153 indexed citations
4.
Zeldin, Robert K., et al.. (2013). Sublingual tablets of house dust mite allergen extracts: Results of a phase I study in adults with mite-associated allergic asthma. European Respiratory Journal. 42(Suppl 57). P3157–P3157. 3 indexed citations
5.
Horak, F., A. Didier, Margitta Worm, et al.. (2012). Improvement In Quality Of Life With Administration Of A 300 IR Sublingual Tablet Of 5-grass Pollen Allergen Extract In Adults With Grass Pollen-induced Allergic Rhinoconjunctivitis. Journal of Allergy and Clinical Immunology. 129(2). AB46–AB46.
6.
Cox, Linda, et al.. (2012). A Us Study Of 5-grass Pollen Allergen Extract In Adults With Grass Pollen-induced Allergic Rhinoconjunctivitis - Results Of Secondary Efficacy Assessments. Journal of Allergy and Clinical Immunology. 129(2). AB46–AB46. 2 indexed citations
7.
Cox, Linda, Thomas B. Casale, Anjuli Nayak, et al.. (2012). Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: The importance of allergen-specific serum IgE. Journal of Allergy and Clinical Immunology. 130(6). 1327–1334.e1. 109 indexed citations
8.
Stewart, Jeffrey, Sarah Moyle, Gerard J. Criner, et al.. (2012). Automated Telecommunication to Obtain Longitudinal Follow-up in a Multicenter Cross-sectional COPD Study. COPD Journal of Chronic Obstructive Pulmonary Disease. 9(5). 466–472. 36 indexed citations
9.
Karpel, Jill P., Marc Massanari, Gregory P. Geba, et al.. (2010). Effectiveness of omalizumab in reducing corticosteroid burden in patients with moderate to severe persistent allergic asthma. Annals of Allergy Asthma & Immunology. 105(6). 465–470. 17 indexed citations
10.
Vogelmeier, Claus, C. Verkindre, D. Cheung, et al.. (2010). Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulmonary Pharmacology & Therapeutics. 23(5). 438–444. 48 indexed citations
11.
Massanari, Marc, Harold S. Nelson, Thomas B. Casale, et al.. (2010). Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. Journal of Allergy and Clinical Immunology. 125(2). 383–389. 166 indexed citations
12.
Massanari, Marc, S.T. Holgate, William W. Busse, et al.. (2009). Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respiratory Medicine. 104(2). 188–196. 92 indexed citations
13.
Kaplan, Allen P., Kusumam Joseph, Robert Maykut, Gregory P. Geba, & Robert K. Zeldin. (2008). Treatment of chronic autoimmune urticaria with omalizumab. Journal of Allergy and Clinical Immunology. 122(3). 569–573. 200 indexed citations
14.
Maykut, Robert, Marc Massanari, Farid Kianifard, et al.. (2005). OMALIZUMAB IMPROVES SYMPTOMS AND REDUCES RESCUE BETA-AGONIST USE IN OLDER PATIENTS WITH UNCONTROLLED ASTHMA. CHEST Journal. 128(4). 243S–243S. 1 indexed citations
15.
Zeldin, Robert K.. (2003). Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. Journal of Antimicrobial Chemotherapy. 53(1). 4–9. 236 indexed citations
16.
17.
Cushman, William C., et al.. (2002). The Effect of a Losartan‐Based Treatment Regimen on Isolated Systolic Hypertension. Journal of Clinical Hypertension. 4(2). 101–107. 98 indexed citations
18.
Katner, Harold, Dávid Paár, Jeffrey P. Nadler, et al.. (2002). Open-Label Study of a Twice-Daily Indinavir 800-mg/Ritonavir 200-mg Regimen in HIV-Infected Adults Failing a Protease Inhibitor Regimen. JAIDS Journal of Acquired Immune Deficiency Syndromes. 31(5). 483–487. 8 indexed citations
19.
Young, Benjamin, Margaret A. Fischl, Tyler S. Finn, et al.. (2002). Open-Label Study of a Twice-Daily Indinavir 800-mg/Ritonavir 100-mg Regimen in Protease Inhibitor–Naive HIV-Infected Adults. JAIDS Journal of Acquired Immune Deficiency Syndromes. 31(5). 478–482. 25 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven E. Carsons Breakdown of academic impact, for papers by Mary Ann Mascelli Breakdown of academic impact, for papers by Céline C. Berthier Breakdown of academic impact, for papers by Gian Carlo Avanzi Breakdown of academic impact, for papers by Eric R. Hurd Breakdown of academic impact, for papers by Katayoon Goodarzi Breakdown of academic impact, for papers by B. Sassolas Breakdown of academic impact, for papers by Hirokazu Imai Breakdown of academic impact, for papers by Gloria R. Gallo Breakdown of academic impact, for papers by Yogendra Kanthi
Rankless by CCL
2026